MENU

CLYM Stock Tickeron detected bullish Stock Pattern: Broadening Wedge Ascending CLYM on August 04, 2025, netting in a 24.12% gain over 2 weeks

A.I.dvisor
at Tickeron.com
Loading...
+24.12% Gain from a Successful pattern Broadening Wedge Ascending
CLYM - Climb Bio Inc
Tickeron
Ticker: CLYM
Company: Climb Bio
Gain: +24.12%
Confirmed: 08/04/25
Succeeded: 08/18/25
Total length: 14 days
On August 04, 2025, A.I.dvisor detected a Broadening Wedge Ascending Pattern (Bullish) for Climb Bio Inc (CLYM, $1.70). On August 04, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $2.03. 14 days later, on August 18, 2025, CLYM reached the target price resulting in a +2 for traders who took a long position in the stock.

CLYM's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CLYM turned positive on August 04, 2025. Looking at past instances where CLYM's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 04, 2025. You may want to consider a long position or call options on CLYM as a result. In of 109 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where CLYM advanced for three days, in of 188 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 52 cases where CLYM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLYM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CLYM broke above its upper Bollinger Band on August 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.868) is normal, around the industry mean (19.343). P/E Ratio (0.000) is within average values for comparable stocks, (54.752). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.643). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (304.274).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CLYM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CLYM showed earnings on August 12, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details